Nutcracker Therapeutics
Guna Kannan is responsible for leading the Protein teams at Nutcracker Therapeutics. In this role, Guna supports the protein engineering/discovery, protein sciences, and analytical teams. He has more than 20 years of protein engineering, antibody engineering/discovery, and developability assessment experiences and has helped develop several novel biotherapeutic platforms and molecules. Prior to joining Nutcracker, Guna was Vice President, Head of Biotherapeutics, at Denali Therapeutics where he helped coordinate activities ranging from target validation to IND-enabling studies with a team of ~40 scientists. He was also Principal Scientist and Protein Engineering and Optimization group head at Amgen Inc where he spent nearly 10 years. Guna has co-authored 60+ peer-reviewed research articles and is a listed patent co-inventor of both clinical molecules and novel platform technologies. He earned his master's degree at the Indian Institute of Technology, a Ph.D. at the Indian Institute of Science, and completed Post-Doctoral studies at the University of Massachusetts, Amherst, MA.
This person is not in any offices
Nutcracker Therapeutics
Nutcracker Therapeutics is an early-stage biotech disrupter founded to develop mRNA-based therapeutic drug products which will be manufactured on the novel ACORN (Automation COntroled RNA) microfluidic-based manufacturing system.